Welcome to our dedicated page for CERo Therapeutics SEC filings (Ticker: CERO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the real story behind CER-T cell breakthroughs often means digging through pages of biotech jargon in CERo Therapeutics’ SEC disclosures. If you have ever wondered why the company’s cash runway shifts quarter to quarter—or need to confirm options exercised by executives—those answers are deep inside the filings and easy to miss.
Stock Titan solves that problem. Our AI reads every document the moment it hits EDGAR, then delivers concise explanations in plain English. Whether it’s a CERo Therapeutics quarterly earnings report 10-Q filing that breaks down R&D spend, or an unexpected 8-K detailing a trial milestone, we surface what matters and link straight to the source. You will even receive CERo Therapeutics Form 4 insider transactions real-time, so you can monitor executive stock moves before markets react.
Here is what you can explore right now:
- CERo Therapeutics annual report 10-K simplified—cash position, pipeline progress, risk factors.
- CERo Therapeutics insider trading Form 4 transactions and executive stock transactions Form 4, complete with trend charts.
- CERo Therapeutics proxy statement executive compensation, summarized to highlight incentive alignment.
- CERo Therapeutics 8-K material events explained—partnerships, clinical data releases, or financings.
Still comparing notes? Use our AI-generated “Key Points” to move from document to decision in minutes. From understanding CERo Therapeutics SEC documents with AI to a deeper CERo Therapeutics earnings report filing analysis, every disclosure is now at your fingertips—updated in real time and explained simply.
CERo Therapeutics Holdings has filed a Prospectus Supplement No. 3 (424B3) updating their May 23, 2025 prospectus for 2,100,000 shares of common stock. The company's stock (NASDAQ: CERO) last traded at $9.56 per share, while its warrants (CEROW) traded at $0.0264.
The key development reported is that the FDA has granted Orphan Drug Designation to the company's lead drug candidate CER-1236 for treating acute myeloid leukemia, as announced on June 17, 2025.
As an emerging growth company, CERo Therapeutics trades on the Nasdaq Capital Market. The filing includes important risk disclosures for investors, and the company has not elected to use the extended transition period for complying with new financial accounting standards.
- Common stock par value: $0.0001 per share
- Warrants: Each exercisable for 1/2000th of a common share
- Principal office: South San Francisco, CA
FAQ
What is the current stock price of CERo Therapeutics (CERO)?
What is the market cap of CERo Therapeutics (CERO)?
What is the core technology behind CERo Therapeutics?
How does CERo’s approach differ from conventional CAR-T therapies?
What are CER-T cells?
Which types of cancer could potentially be targeted by CERo’s therapies?
What evidence supports the safety profile of CERo’s lead candidate?
How does CERo approach manufacturing for its engineered T cells?
What role do regulatory engagements play in CERo's development strategy?
How does CERo contribute to the broader oncology research community?
